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Abstract
Heterotrimeric G-proteins, comprising Gα, Gβ, and Gγ subunits, are molecular switches that regulate
numerous signaling pathways involved in cellular physiology. This characteristic is achieved by the
adoption of two principal states: an inactive state in which GDP-bound Gα is complexed with the
Gβγ dimer, and an active state in which GTP-bound Gα is freed of its Gβγ binding partner. Structural
studies have illustrated the basis for the distinct conformations of these states which are regulated
by alterations in three precise ‘switch regions’ of the Gα subunit. Discrete differences in conformation
between GDP- and GTP-bound Gαunderlie its nucleotide-dependent protein-protein interactions
(e.g., with Gβγ/receptor and effectors, respectively) that are critical for maintaining their proper
nucleotide cycling and signaling properties. Recently, several screening approaches have been used
to identify peptide sequences capable of interacting with Gα (and free Gβγ) in nucleotide-dependent
fashions. These peptides have demonstrated applications in direct modulation of the nucleotide cycle,
assessing the structural basis for aspects of Gα and Gβγ signaling, and serving as biosensor tools in
assays for Gα activation including high-throughput drug screening. In this review, we highlight some
of the methods used for such discoveries and discuss the insights that can be gleaned from application
of these identified peptides.
Introduction
Diverse extracellular signals, including hormones, neurotransmitters, growth factors, and
sensory stimuli, transmit information intracellularly by activation of plasma membrane-bound
receptors. The largest class of such receptors is the superfamily of heptahelical G protein-
coupled receptors (GPCRs). GPCRs transmit signals by activating heterotrimeric G-proteins
that normally exist in an inactive state of Gα·GDP bound to Gβγ subunits. In the traditional
model (Figure 1), agonist activation of GPCRs induces incompletely defined conformational
changes within the receptor, which subsequently catalyze the exchange of GDP for GTP on
the Gα subunit by inducing conformational changes within Gαβγ that lower the affinity for
GDP allowing for nucleotide release and subsequent GTP binding [1–3]. By this means,
GPCRs serve as guanine nucleotide exchange factors (GEFs) for Gα·GDP/Gβγ complexes.
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Although the exact mechanism by which GPCRs exert their GEF activity remains to be fully
elucidated [3], this action is critical to the commencement of G protein signaling, as GDP
release is the rate-limiting step of the Gα guanine nucleotide cycle [4]. Subsequent to GDP
release, GTP, a nucleotide present in a relative excess, binds Gα and induces a conformational
change in three flexible ‘switch regions’ of the Gα subunit, which deforms the Gβγ binding
interface leading to both the dissociation of the Gβγ dimer as well as the adoption of the
conformation capable of interacting with effectors [1,5]. Activated Gα·GTP and liberated
Gβγ both signal to a diverse family of downstream effectors including ion channels, adenylyl
cyclases, phosphodiesterases, and phospholipases, producing second messenger molecules that
regulate cellular responses underlying physiological processes [2]. Based on their sequence
homology and differential regulation of effectors, G-proteins are grouped in four classes:
Gαs, Gα/o, Gαq, and Gα12/13 [6]. GPCRs have the ability to couple selectively to members of
one or more of these G-protein subfamilies, thus allowing selective modulation of signaling
cascades by particular GPCR ligands. G-protein signaling is terminated by the intrinsic GTPase
activity of the Gα subunit, which occurs at a rate that varies among the G-protein subfamilies.
GTP hydrolysis rates can be dramatically enhanced by members of a superfamily of “regulators
of G-protein signaling” (RGS) proteins [7–9] that serve as GTPase-accelerating proteins (or
“GAPs”). This deactivation reaction results in conversion back to the inactivated, GDP-bound
Gα that subsequently reassociates with Gβγ to complete the cycle. Because this represents a
true cycle of activation (by nucleotide exchange and subunit dissocation) and deactivation (by
GTP hydrolysis and subunit reassociation), heterotrimeric G-proteins serve as molecular
switches and are critical to defining the spatial and temporal aspects of cellular responses to
external stimuli.
Biochemical and structural analyses over the past two decades have advanced our
understanding of the mechanics underlying G-protein regulation and the guanine nucleotide
cycle [3,10]. As previously alluded to, the structural basis for this activation cycle is governed
principally by three Gα switch regions -- flexible segments that change conformation upon
GTP binding and hydrolysis. Indeed, the switch regions contain high sequence conservation
among G-proteins, especially in those residue positions that are directly involved in nucleotide
binding, GTP hydrolysis, and protein-protein interactions (e.g. Gβγ, RGS proteins, effectors)
[3,10]. Given that conformational changes to these switch regions are crucial to the G-protein
signaling cycle, further defining the structural and biochemical nature of these distinct
signaling states of Gα should provide further insight into G-protein signaling dynamics and
greatly facilitate assay development and target validation for drug discovery.
Screening methods have been developed to identify randomized peptide sequences capable of
interacting with target proteins as a means of creating novel binding partners for signaling
proteins of interest [11–13]. Recently, such screening methods have been utilized to develop
peptides capable of interacting with Gα and Gβγ subunits. In the case of Gα, nucleotide-state
specific peptides have been identified by selectively screening against both inactive and active
conformations. These peptides have been used to gain additional biochemical and structural
insights into the signaling dynamics of heterotrimeric G-proteins. Additionally, several diverse
applications have been made of these peptides towards the identification of small molecule
drugs that modulate G-protein activity both directly and indirectly, with the ultimate goal of
facilitating novel GPCR screening methods. This review will highlight the current successes
in the screening for, and early uses of, G-protein binding peptides.
Screening Methods
Several in vitro methods have been developed to identify and evolve peptide sequences that
interact specifically with target proteins of interest (e.g., refs. [11–13]). Although technically
different in several design aspects, these various methods all entail certain fundamental criteria.
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Each process begins with the assembly of a diverse, randomized cDNA library suitable for
translation into diverse peptide sequences of desired length (although certain a priori
constraints on sequence complexity can be employed if desired). A method for expressing this
library must then be developed to physically link the cDNA sequence to its associated, encoded
peptide. Popular methods currently employed for this process include peptides-on-plasmids
[14], phage display [13,15,16], and mRNA display [17]. Once such a library of nucleic acid-
tethered peptides is generated, the next step involves affinity selection against a desired protein
target that is typically immobilized for retaining bound peptides (and their tethered genetic
information) and removing non-specific peptides through extensive washing procedures.
Sequences found to interact selectively with target proteins are then amplified, thereby
producing an enriched library. This library is then typically subjected to further rounds of the
selection process to enrich further the target library. Moreover, sequences identified can also
be used for further targeted evolution of second-generation libraries. This entire process can
be repeated until particular polypeptide sequences of desired quality (e.g., affinity and
selectivity) are identified. Cloning and DNA sequencing ultimately defines the amino acid
sequence of binding peptides. These in vitro techniques can effectively screen libraries as
diverse as 108 to 1013 unique peptide sequences [18,19]. Numerous alternative approaches to
identify affinity reagents, such as mass spectrometry/proteomic approaches to peptide library
screening, have been discussed in depth elsewhere [20].
The discoveries highlighted herein focus primarily on the techniques of phage display and
mRNA display, both recently successful in identifying both Gα- and Gβγ-binding peptides.
These peptides represent useful new tools for investigating the biochemical and structural
dynamics of G-protein signal transduction.
Biochemical Insights
KB-752 – a Gα·GDP-selective phage-display peptide
Recent studies using phage display analysis have identified novel Gα binding peptides [16,
21–23]. Some of these peptides are capable of interacting selectively with either the inactive
(GDP-bound) or active (GTP-bound) conformation of Gα [21–23]. A GDP-selective peptide,
KB-752 (Table I), was initially demonstrated to interact most avidly with Gαi1–3 family
members [23]. KB-752 interaction with Gαi1·GDP results in an enhancement of spontaneous
nucleotide exchange; thus, KB-752 serves as a Gαi1 GEF [23]. This result illustrates the
potential usefulness of identified peptides in biochemical studies of G-protein signaling, as the
native GEFs for Gα (i.e., GPCRs) are notoriously difficult to produce given that they are
integral membrane proteins. Subsequent studies revealed that KB-752 was also capable of
binding the inactive conformation of Gαs [22]. Interestingly, interaction with Gαs results in
guanine nucleotide dissociation inhibitor (GDI) activity, the opposite action to that elicited
towards Gαi1. By virtue of these synergistic activities on both Gαi and Gαs, KB-752 inhibits
GTPβS-stimulated adenylyl cyclase activation in cell membranes [22]. Together, these results
demonstrate several unique biochemical properties of KB-752 potentially useful to the
investigation of G-protein mediated signaling pathways.
KB-1753 and two other peptide families with affinity for activated Gα subunits
Our phage display screening technique has also yielded peptides that specifically bind the
activated conformation of Gα. We recently published on the identification of KB-1753 (Table
I), which interacts with selective Gα subunits in both the GTP-bound conformation and
(especially) the transition-state mimetic, GDP·AlF4−-bound conformation [21]. In vitro
experiments demonstrated that, by binding to GTP-bound Gα, KB-1753 blocks the interaction
of Gαt with its effector, PDEγ, and prevents stimulation of cyclic GMP degradation. Binding
of the transition state Gα results in an analogous inhibition of RGS protein interaction and
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resultant GAP activity [21]. These results highlight the usefulness of KB-1753 as a potential
tool for blocking both Gα signaling to effector molecules as well as RGS protein activity for
Gα. Direct inhibition of Gα signaling has been suggested as an alternative therapeutic target
to traditional modulation of receptor activity [24,25]. Inhibitors of RGS proteins, including
both peptidomimetics and small molecules, represent another potentially attractive route of
drug discovery targeting G-protein signaling pathways [7,26,27] (cf. [28]). KB-1753 may
therefore serve as a useful template for future design of such strategies (see below). In addition
to these biochemical properties, KB-1753 has been modified to act as a biosensor for activated
Gα [21]. By tagging the peptide with YFP, KB-1753-YFP served as the acceptor to the Gαi1-
CFP donor in a FRET-based biosensor pair in vitro. Such probes, along with other dye-based
approaches, provide a starting point for the design of in vivo applicable probes that may help
unravel the spatiotemporal dynamics of G-protein signaling in living cells [29,30].
In our original phage display screen [23], we identified two additional groups of activated-
state-dependent, Gαi-binding peptides with distinct sequence homology compared to the
KB-1753 group. These two groups have been termed the KB-1746 and KB-1755 groups (Figure
2) after the representative peptide sequence from each that was further characterized (Table I).
In contrast to the GV/IWxG motif of the KB-1753 group [21], the KB-1746 and KB-1755
groups display consensus motifs of CxGWxCY and I/VCPWE/D, respectively (Figure 2). These
results suggest that distinct sequence motifs within multiple peptide groups can each selectively
recognize the activated conformation of Gα in common.
To quantitate the affinity of the interaction of KB-1746 and KB-1755 with Gα, we used both
fluorescence anisotropy and surface plasmon resonance (SPR) assays. To determine binding
affinities in a solution-based assay, we first synthesized N-terminal FITC-labeled KB-1746
and KB-1755 peptides and investigated their interaction with Gαusing fluorescence anisotropy.
KB-1746 and KB-1755 interacted with Gαi1·GDP·AlF4−and Gαt/i1·GDP·AlF4− with binding
affinities (KD values) of approximately 1.0 and 1.8 μM, respectively (Figure 3) – both values
comparable to the previously determined binding affinity of KB-1753 for its Gαi1 target (KD
of 1.2 μM; ref. [21]). Follow-up SPR experiments involved the injection of various Gα isoforms
(in specific nucleotide-bound forms) over N-terminally biotinylated KB-series peptides
immobilized on a streptavidin-coated gold biosensor chip (Figure 4). Observed interactions
were in general agreement with the nucleotide-state-selective nature of these binding events
first observed in the initial phage screening and phage ELISA results [23], although the
KB-1746 peptide displayed more modest nucleotide selectivity in showing some affinity also
for the inactive, GDP-bound conformation of Gαi1 (e.g., Figure 4B). As originally reported
[21], KB-1753 interacted solely with Gα subunits in their active conformation (Figure 4A,D),
including Gαi1, Gαi2, Gαi3, and Gα-transducin (the latter actually an E. coli-purifiable Gαt/i1
chimera that closely mimics the biology of Gα-transducin; refs. [21,31]). KB-1746 displayed
a similar Gα subfamily selectivity profile to that of KB-1753; however, a robust interaction
with Gαo was also detected (Figure 4E). This Gαo/KB-1746 interaction is unique, as neither
KB-1753 nor KB-1755 is capable of binding this particular Gα subunit despite its high degree
of sequence similarity to Gαi subunits in the predicted peptide-binding site [21]. Although
KB-1755 showed significant binding to Gαi1, Gαi2, and Gαi3, its interaction with Gαt was even
more robust (Figure 4F), suggesting that this peptide has a relative Gαt selectivity unseen in
the other two peptide groups. Overall, these results highlight the similar preference all three
peptide groups possess for the activated Gα conformation, as well as differing Gα subunit
preferences of specific peptides.
Our previous biochemical and structural studies of KB-1753 demonstrated a mode of binding
to activated Gα analogous to that of effectors, with the specific site of interaction comprising
the highly conserved hydrophobic α2/α3 cleft of Gα [21]. To investigate whether KB-1746
and KB-1755 peptides bind to the same site on Gαi1, we carried out competition binding
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analyses again using surface plasmon resonance. SPR surfaces of biotinylated KB-1753 (as a
control), KB-1746, and KB-1755 were created and their interaction with activated Gαi1 was
examined in the absence and presence of increasing concentrations of non-biotinylated
KB-1753 peptide (Figure 5). As expected, unlabelled wildtype KB-1753 peptide was capable
of competing for Gαi1 binding to the immobilized KB-1753 surface. A loss-of-function mutant
KB-1753 peptide (Ile-9 and Trp-10 mutated to alanine; “I9A/W10A”), which does not bind
Gαi1 [21], was ineffective at competing for Gαi1 binding (Figure 5A). Wildtype KB-1753
peptide was also capable of precluding binding of Gαi1 to the immobilized KB-1755 surface,
suggesting that the binding site for KB-1755 at least partially overlaps with that of KB-1753
(Figure 5C). However, preincubation with KB-1753 did not significantly alter the binding of
Gαi1 to the immobilized KB-1746 surface (Figure 5B), suggesting that KB-1746 interacts
through a novel binding site distinct from that of KB-1753.
To more completely investigate the interaction of KB-1746 and KB-1755 with activated Gα
and map the interaction site, we conducted fluorescence-based binding experiments in the
presence of potential competitors for Gα binding. Analogous to our prior studies with FITC-
labelled KB-752 and R6A-1 peptides [22,32], we observed that FITC-labelled KB-1755
undergoes a significant (~30%) and reproducible enhancement of fluorescence quantum yield
upon binding to activated Gα (Figure 6). Using this approach, we conducted competition
binding studies and found that all three classes of activation-state-selective peptides compete
with FITC-KB-1755 for binding to Gαi1·GDP·AlF4− (Figure 6A). The KB-1753 result is in
agreement with the SPR analysis described above (Figure 5C). The ability of KB-1746 to
compete with FITC-KB-1755, despite its inability to be competed by KB-1753 (Figure 5B),
suggests that KB-1755 shares contacts on Gα with the two distinct binding sites created by
KB-1746 and KB-1753.
To further explore the binding of KB-1755, we also assessed the ability of an RGS protein
(RGS16) and an effector peptide (PDEγ) to compete for binding to Gαt/i1. RGS proteins and
effectors both bind the active conformation of Gα subunits, but have distinct, non-overlapping
binding sites [33,34]. RGS16 and PDEγ each competed with FITC-KB-1755 for Gαt/i1 binding,
reducing nearly equally the observed EC50 of the latter, fluorophore-labeled peptide (Figure
6B). Thus, the KB-1755 peptide likely interacts with Gα in a mode that extends partially
through both the effector- and RGS protein-binding sites. As KB-1753 binds predominantly
to the effector binding site of Gα [21], this suggests that KB-1746 potentially interacts
predominantly with the RGS protein binding site of Gα.
Derivatives of the GoLoco motif
As an alternative approach to phage display, mRNA display has also been used for identifying
novel Gα binding sequences. Ja and Roberts recently described a class of Gα binding peptides
with the prototype sequence termed R6A ([35]; Table I). In contrast to the completely random
screening approach employed in our phage display studies, the mRNA display of Ja and Roberts
was done using an a priori input sequence: namely, that of the consensus motif for the GoLoco
motif (also known as the GPR motif) [36]. The naturally-occuring GoLoco motif, found in
known GPCR signaling regulators such as RGS12 and RGS14, binds Gαi/o subunits
preferentially in the GDP-bound form and inhibits spontaneous nucleotide release (i.e., guanine
nucleotide dissociation inhibitor or “GDI” activity; [37,38]. Not surprisingly, R6A and other
peptides patterned after the GoLoco motif also interact with Gα·GDP and have apparent
binding affinities of 60~200 nM [35]. Despite containing a non-conservative replacement of
the critical arginine residue in the signature Asp-Gln-Arg motif of the GoLoco motif [36], the
R6A family of peptides was initially reported to have GDI activity similar to that of the parent
GoLoco motif peptide [35]. However, more careful exploration using multiple modes of
measuring nucleotide binding and cycling suggested that, while the R6A-1 peptide does
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interact with Gα·GDP, it does not elicit any significant GDI activity [32]. The R6A-1 peptide,
a minimal 9-mer representing the R6A family (Table I) and possessing sequence similarity to
KB-752 [32], was further reported to bind to all Gα family members in their GDP-liganded
forms and this binding was mutually exclusive with Gβγ binding [39]. One could imagine the
R6A family of peptides, as well as their naturally-occuring GoLoco motif progenitors, may
prove useful as Gα-interacting peptides that occlude Gβγ interaction for studying the regulation
of heterotrimer association/dissociation related to the temporal aspects of G-protein signaling.
Gβγ-interacting peptides
In addition to screens for Gα-interacting peptides, the isolated Gβγ subunit has also been used
as the bait for discovery of novel binding sequences. Smrcka and colleagues used randomized
peptide libraries in a phage display screen to identify four distinct groups of Gβγ binding
peptides [40]. Peptides in ‘group I’ had a consensus motif with homology to two native Gβγ
binding proteins, PLCβ and phosducin, while ‘groups II-IV’ had little homology to known
proteins or to that of group I peptides ([40] and see Table I). Interestingly, a peptide with the
strongest correlation to the group I consensus, termed SIRK, was capable of selectively
inhibiting Gβγ-mediated activation of PLCβ while not affecting Gβγ stimulation of voltage-
gated calcium channels or type I adenylyl cyclases. Despite divergent sequences, competition
experiments revealed peptides from all four groups bound the same site on Gβγ, which was
termed the Gβγ ‘hot spot’ that is likely used for selectivity among effector interactions. [40].
This elegant study has thus produced inhibitory peptides capable of dissecting among several
Gβγ-mediated signaling pathways, which will undoubtedly prove to be valuable tools for
studying these pathways both in vitro and in vivo.
Structural Insights
KB-752/Gαi1·GDP complex
We recently elucidated the structural determinants of Gαi1 binding by the GDP-selective phage
peptide KB-752 to high resolution using x-ray diffraction crystallography [23]. In mimicking
the biochemical activity of a receptor (i.e., GEF activity), and representing a much more
tractable target for structural studies than a membrane-bound GPCR, the KB-752 peptide was
instrumental to understanding mechanistic details of Gα activation, which remains poorly
understood [3]. The crystal structure of the Gαi1/KB-752 dimer revealed a peptide binding site
centered on the hydrophobic α2/α3 cleft of the Gα Ras-like domain [23] (Figure 7A). Binding
of KB-752 levers the conformationally-flexible switch II (α2) helix in a direction away from
the GDP binding site. In turn, this alteration causes the preceding β3/α2 loop to assume a novel
conformation, stabilized by interactions with KB-752, that removes it from its normal
disposition within the Gαi1β1γ2 heterotrimer. In the heterotrimer structure [41], as well as the
Gαi1/RGS14-GoLoco structure [38], this β3/α2 loop sits directly in front of the bound GDP
molecule. It is thought that this conformation, when bound to either of these GDI proteins,
allows the β3/α2 loop to serve as an ‘occlusive barrier’ to the release of GDP and, furthermore,
that receptors use Gβγ as a ‘lever’ to remove this barrier allowing for nucleotide exchange
[3,42,43]. That KB-752 induces such a conformational change in the β3/α2 loop likely explains
its GEF activity for Gαi1. Thus, KB-752, identified using phage display, has provided insight
into the mechanism of G-protein activation by giving structural support to a previously
proposed model of receptor-mediated activation [42,43].
KB-1753/Gαi1·GDP·AlF4− complex
We have also elucidated the high-resolution structural determinants of the interaction of the
activation-state-dependent phage peptide KB-1753 bound to Gαi1 in its transition-state
(GDP·AlF4−) conformation [21]. KB-1753 was found to bind the same α2/α3 cleft within
Gα as was seen with KB-752 (Figure 7B). The stringent reversal in nucleotide selectivity
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between these two peptides (Table I) is due to the difference in peptide residues that insert in
this same hydrophobic groove: the larger tryptophan in KB-752 requires a flexible α2 helix
found only in the GDP-bound form, whereas the smaller isoleucine in KB-1753 is perfectly
accommodated by the more closed and rigid conformation of the α2 helix found in the active
conformation ([21,23] and see Figure 7A,B). The Gα/KB-1753 complex revealed a striking
similarity to native Gα/effector complexes and, thus, represents the first structural glimpse of
an ‘effector-like molecule’ bound to Gαi1. Although the Gα residues contacted by KB-1753
are strictly conserved among all Gα families, KB-1753 displays a narrow selectivity profile
for specific Gαi subfamily members [21], even discriminating within this subfamily against
Gαo (Figure 4D). These results have implications for the nature of specificity determinants
within Gα/effector interactions, supporting the notion that specificity for particular Gα
subfamily members can be determined by differences, even subtle, in effector sequence and
structure [34]. Structural information on the Gα/KB-1753 complex will undoubtedly aid in the
rational design of future biosensors as previously described above. Another application made
possible by this crystal structure is structure-based design and screening of small molecule
inhibitors of Gα signaling. Analogous efforts using Gβγ have already proven fruitful ([44] and
see discussion below).
SIGK/Gβ1γ2 complex
A crystal structure of Gβ1γ2 bound to a SIRK peptide derivative (denoted “SIGK”; Table I)
has been determined, depicting the molecular basis for this peptide’s unique regulatory
properties [45]. The SIGK peptide assumes a partial α-helical conformation reminiscent of the
switch II helix of Gα within the Gαβγ heterotrimer (Figure 7C). Moreover, the SIGK helical
peptide binds the same face of Gβ1γ2 as does switch II. This common binding site likely
explains the apparent ability of this peptide to induce G-protein heterotrimer dissociation
[46,47]. It is interesting to note that Gβ1γ2 uses both polar and nonpolar residues in the overall
SIGK binding interface, suggesting that this combination of binding determinants dictates the
ability of Gβ1γ2 to recognize a variety of downstream effector binding partners. In support of
this notion, mutation of selective Gβ1γ2 residues within the Gβ1γ2/SIGK interface [45] resulted
in loss of binding to different subset(s) of the four distinct groups of Gβγ-binding peptides
originally isolated by Smrcka and colleagues [40]. Thus, effectors likely share the common
overall SIGK-footprint for interaction with Gβ1γ2, yet distinct sets of interactions within this
Gβγ ‘hot spot’ dictate the specificity of each given complex [45].
‘Hot spots’ have been proposed to represent unique areas within proteins for guiding targeted
drug design efforts [48]. Data from the SIGK family of peptides has defined such an area within
Gβ1γ2. The ability of these phage display peptides to selectively perturb Gβ1γ2 signaling nodes
[40] further implies that drug design to this particular ‘hot spot’ may lead to the identification
of small molecules capable of inhibiting specific Gβγ-driven signal transduction pathways.
Such a discovery has recently been reported using the Gβ1γ2/SIGK interface as the basis for
computational docking screens of virtual compound libraries [44]. Several Gβ1γ2 binding
compounds were identified in this in silico screen and subsequently shown to selectively
modulate Gβ1γ2 signaling both in vitro and in vivo. M119, a fluorescein-like lead compound
from this virtual screening, was capable of blocking Gβ1γ2/SIGK interaction, inhibiting
Gβ1γ2 activation of purified PLCβ2, preventing chemoattractant-induced calcium signaling in
intact immune cells, and sensitizing mice to the antinociceptive effects of morphine in vivo
[44]. These sensational findings demonstrate perhaps the ultimate application of peptide
screening studies, given that the original finding of the SIRK phage-display peptide formed
the basis for the discovery of the small molecule Gβγ-inhibitor M119. Analogous screens using
the Gαi1/KB-1753 complex could be envisioned to identify useful small molecule inhibitors
of Gα signaling. (Note that we are not suggesting that heterotrimeric G-protein alpha subunits
will necessarily emerge as drug targets themselves, except possibily in the case of their
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mutational activation (as for GNAS in endocrine tumors; ref. [49]). However, there is a real
need for chemical biology approaches to target heterotrimeric G-protein function and thus
further delineate the biology of these signaling molecules as well as facilitate new screening
paradigms. A germane example is the Gαq-selective inhibitor YM-254890, which is likely to
provide novel biological insights [50,51].)
Application in High-Throughput Screening for GPCR Modulators
The original intent of our efforts in identifying nucleotide-state-selective Gα-binding peptides
was to employ them in developing rapid, non-radioactive means for assaying heterotrimeric
G-protein activation by GPCRs. In particular, peptides that show specificity towards the active,
GTP-bound state of Gα subunits (such as KB-1753, KB-1746, and KB-1755) or freed Gβγ
subunits (such as SIRK and SIGK) should be valuable tools in detecting receptor-mediated
heterotrimer activation when coupled to a real-time, sensitive readout of their specific G-
protein subunit interaction (e.g., the FITC-labelled KB-1755 shown in Figure 6A). In pilot
studies previously described [52], we have shown that activation-state-selective Gα-binding
peptides are able to faithfully report on several different GPCR/heterotrimer complexes when
their activation status has been modulated by specific agonists and antagonists (Figure 8). In
examining the Gi-heterotrimer coupled M2 muscarinic acetylcholine receptor (M2-mAChR),
we have observed that binding of the Gαi·GTP-specific peptide KB-1755 to immobilized
membrane preparations is significantly higher in the presence of the receptor-specific agonist
carbachol than in its absence; furthermore, this binding was inhibited in a dose-dependent
manner by the receptor-specific antagonist atropine, a clear indication that the effect is receptor
promoted (Figure 8A).
Gαi·GTP-specific peptides, besides being useful in detecting activation or inactivation of a
Gi-coupled GPCR, can also be employed in conjunction with chimeric Gα subunits (reviewed
in [53]) to detect activation or inactivation of a GPCR which normally couples to a different
G-protein such as Gαq or Gαs. For example, to demonstrate utility in measuring β2-adrenergic
receptor (β2-AR) status upon treatment with agonist isoproterenol and inverse agonist
ICI-118,551 (Figure 8B), we employed a Gαi6s chimera [54] in which the last 6 residues of
Gαi1 (KDCGLF) were replaced with the last 6 residues of Gαs (RQYELL), thus allowing
functional coupling of a Gαi6s/Gβγ heterotrimer to the normally Gs-coupled β2-AR [55]. We
further confirmed the utility of this chimeric Gα strategy in detecting dose-dependent activation
of the dopamine D1-receptor (another normally Gs-coupled receptor [56]; Figure 8C). We have
also used this peptide-based assay to recapitulate the known relative efficacies and rank order
of potencies of the β2-AR agonists isoproterenol, salbutamol, and dobutamine (refs. [52,57];
Figure 8D); all activation signals from these agonists were inhibited by the inverse agonist
ICI-118,551 (data not shown). These latter results indicate that the known pharmacological
properties of the β2-adrenergic receptor are faithfully preserved in this Gαi·GTP-specific
peptide-based activation assay. Additional screening for activation-state-selective phage
peptides specifically directed to Gαs and other Gα subfamilies (e.g., Gαq, Gα12/13) should
obviate the need to reconstitute GPCR/heterotrimer complexes with chimeric Gαi subunits.
We conducted a pilot screening assay in 96-well plates using baculovirus-infected Sf9 cells to
investigate the applicability of the M2-mAChR assay for high-throughput screening. The
screen was performed on the Library of Pharmacologically Active Compounds (LOPAC;
Sigma-Aldrich), with compounds applied at a final concentration of 1 μM. Twelve documented
cholinergic agonists were detected with responses greater than 50% of the signal observed with
a saturating dose (10 nM) of oxotremorine. Representative examples including the agonists
arecoline, dioxolane, carbachol and the antagonist atropine are annotated in Figure 9. The Z-
factor of the assay was calculated as 0.62, indicative of a robust and sensitive screening assay
[58]. The compound TMB-8 (3,4,5-trimethoxybenzoic acid 8-[diethylamino]octyl ester) was
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also identified as an M2-mAChR agonist in our pilot screen. The peptide-detection assay was
then used to directly compare TMB-8 and carbachol for M2-mAChR activation (Figure 10A).
In terms of G-protein agonism, the two compounds were similar in potency, while the
traditional agonist carabachol had a two-fold greater efficacy. Antagonist competition
experiments were consistent with this data (Figure 10B). As a positive control, we examined
the guanine nucleotide selectivity of the assay and demonstrated that G-protein activation could
only be detected in the presence of micromolar GTPγS but not GDP (Figure 10C). TMB-8 has
previously been characterized as a muscarinic antagonist [59] and an allosteric modulator of
the M2 muscarinic acetylcholine receptor [60]. TMB-8 slows the rate of binding and the
dissociation of pre-bound acetylcholine from the M2 muscarinic receptor [61]. Our data are
interesting in that they demonstrate that TMB-8 has canonical agonist-like properties at the
M2-mAChR with regard to G-protein activation (Figure 10A). However, we have not
conducted the mechanistic studies necessary to confirm or refute TMB-8 as an allosteric
modulator of the M2-mAChR. In this regard, it must be noted that TMB-8 has multiple
pharmacologic effects and targets, having been originally characterized as a calcium
anatagonist [62,63]. Therefore our discovery via this pilot, peptide-based GPCR screen that
TMB-8 is an agonist at the M2 muscarinic acetylcholine receptor is a novel pharmacological
finding.
Concluding Remarks
G-protein subunit binding peptides, identified by various screening methods, have presented
themselves as powerful research tools for studying target proteins within vital signal
transduction pathways. As described herein, these peptides have numerous applications
including:
1. Serving as direct modulators of target protein activity,
2. Providing structural insights into previously undefined mechanisms of target protein
function,
3. Supplying a template for designing biosensors capable of reporting the spatiotemporal
dynamics of target protein signaling,
4. Presenting a model for screening small molecule libraries to identify inhibitors of
target G-protein subunit activity, and
5. Serving as the starting material for novel, non-radioactive assays for measuring
agonist and antagonist activity on GPCR/heterotrimer complexes.
Recently, screening methods including phage-display and mRNA-display techniques have
successfully identified such peptides targeting both Gα and Gβγ subunits [12,16,21,23,35,39,
40]. These peptides have already given valuable insights into various aspects of G-protein
signaling and have been elegantly applied in various scenarios just described. Continued efforts
to identify novel peptide sequences to additional G-protein subfamilies should afford further
discoveries into heterotrimer nucleotide cycling as well as future assay platforms for receptor-
mediated G-protein signaling.
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The traditional model of the guanine nucleotide exchange and hydrolysis cycle governing the
receptor-mediated activation of heterotrimeric G protein-coupled signal transduction. GPCRs
bind, via their intracellular loops, to the heterotrimeric G-protein consisting of Gα (with bound
GDP) associated with the Gβγ dimer. The isoprenylated Gβγ dimer aids in association of the
heterotrimer with the plasma membrane, participates in receptor coupling, and serves as a
guanine nucleotide dissociation inhibitor (GDI) preventing spontaneous activation of the Gα
subunit. Agonist-bound receptors act as guanine nucleotide exchange factors (GEFs) by
provoking conformational changes in Gαβγ resulting in the release of GDP and binding of GTP
by the Gα subunit. Binding of GTP induces changes in three flexible switch regions within the
Gα subunit, leading to Gβγ dimer dissociation. Both Gα·GTP and freed Gβγ dimer subsequently
regulate downstream effectors, either alone or in a coordinated fashion. The GPCR/
heterotrimer complex returns to the inactive state by the intrinsic GTP hydrolysis activity of
Gα, cleaving the terminal γ-phosphate from GTP and rendering Gα again bound to GDP and
reassociated with the Gβγ dimer, thus mutually terminating the signaling capacity of both
subunits of the heterotrimer. GTP hydrolysis is greatly enhanced by the “regulator of G-protein
signaling” (RGS) family of proteins, which serve as GTPase-accelerating proteins (GAPs) for
the Gα subunit.
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Multiple sequence alignments of the (A) KB-1753, (B) KB-1746, and (C) KB-1755 groups of
phage-display peptide sequences with affinity for activated Gαi subunits, with consensus
sequence elements denoted above each grouping. Sequence alignments were created using
ClustalW and BOXSHADE programs. (Note that the N-terminal and C-terminal SS and SR
dipeptide sequences are generated during cloning and thus typically not involved in the peptide/
Gα interaction; e.g., refs. [21,23])
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Fluorescence anisotropy was used to measure the equilibrium affinity of interaction between
Gα subunits and 10 nM of FITC-KB-1746 or FITC-KB-1755 peptides. Equilibrium
fluorescence anisotropy was measured in the presence of increasing concentrations of
Gαi1·GDP·AlF4− (for KB-1746; grey) or Gαt/i1·GDP·AlF4−(for KB-1755; black). 95%
confidence intervals for KD determinations were: KB-1746, 0.86 - 1.2 μM; KB-1755, 1.4 - 2.1
μM.
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Surface plasmon resonance (SPR) biosensor assays demonstrating nucleotide-selective (A-C)
and Gα subfamily-selective (D-F) binding to immobilized KB-series peptides. SPR assays were
conducted as previously described (refs. [21–23]), with biotinylated KB-series peptides
immobilized on separate streptavidin biosensor surfaces to relative surface densities of ~500
RU and indicated Gα subunit analytes (each at 5 μM) injected for 360 seconds (in GDP or
GDP·AlF4− [“AMF”] nucleotide states as indicated in panels A-C; solely in GDP·AlF4−
nucleotide state in panels D-F).
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SPR biosensor competition binding assays, conducted in a similar fashion to panels D-F of
Figure 4 and using 1 μM Gαi1·GDP·AlF4− preincubated with the indicated concentrations of
wildtype or loss-of-function (I9A/W10A mutant) KB-1753 peptide prior to injection over
indicated immobilized peptide surfaces.
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Fluorescence spectroscopic assays were used to measure competitive binding interactions
between peptides (and proteins) that bind to activated Gα subunits. (A) FITC-labeled KB-1755
peptide was used as a conformation-sensitive reporter for Gα binding. The fluorescence
emission spectrum of 1 μM FITC-KB-1755 was measured in the presence of DMSO vehicle
or 10 μM competitor peptides: biotin-KB-1746, biotin-KB-1753, or biotin-KB-1755 (control
[“CTRL”] spectra in grey). 3 μM of Gαi1·GDP·AlF4− was then added and fluorescence
emission was re-measured after 5 minutes (black spectra). Data are presented as the average
of triplicate determinations. The net fluorescence enhancement was calculated in percent.
Percent fluorescence enhancement (±SEM): DMSO (26.2 ±1%), KB-1746 (6.9 ±1%),
KB-1753 (9.4 ±1%), KB-1755 (6.0 ±1%). RFU = relative fluorescence units. (B) Equilibrium
fluorescence anisotropy assays were conducted using 10 nM FITC-KB-1755 and increasing
concentrations of Gαt/i1·GDP·AlF4−. Titrations were conducted in the presence of DMSO
vehicle or indicated concentration of competitor proteins/peptides: biotin-KB-1746, biotin-
KB-1753, biotin-KB-1755, RGS16 (aa 53–190, spanning the minimal RGS domain), or biotin-
PDEγ (aa 63–87). Data are presented as EC50 values (with 95% confidence intervals) of the
fluorescence increase derived from the FITC-KB-1755/Gαt/i1·GDP·AlF4− interaction.
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Structures of G-protein subunit-selective peptides and their G-protein partners (see color
version on cover of this issue). (A, B) Overall structural features of the KB-752/Gαi1·GDP
(panel A) and KB-1753/Gαi1·GDP·AlF4− (panel B) complexes as obtained by X-ray diffraction
crystallography [21,23]. Both KB-752 and KB-1753 peptides (red) are found situated in a
groove between the α2 (“switch II”) and α3 helices of the Gα Ras-like domain (blue; switch
regions in green); no contacts are made by either peptide to the Gα all-helical domain
(yellow) nor GDP moiety (magenta). Bound magnesium and aluminum tetrafluoride ion are
colored orange and grey, respectively, in panel B. (C) Overall structural features of the SIGK/
Gβ1γ2 complex as obtained by X-ray diffraction crystallography [45]. The SIGK peptide
(red) lies in an α-helical conformation over the top of the β-propeller (or “torus”) structure of
the Gβ subunit (cyan); no contacts are made to the Gγ subunit (black).
Johnston et al. Page 19














Examples of using activation-state-selective, Gα-binding peptides to measure GPCR/
heterotrimer activation state upon agonist and antagonist treatment. (A) Peptide-based assay
of M2-muscarinic acetylcholine receptor (M2-mAChR) stimulation and inhibition.
Membranes of Sf9 insect cells co-infected with baculoviruses expressing M2-mAChR, Gαi1,
and Gβ1γ2 subunits were prepared by nitrogen cavitation; 10 μg of membrane protein per well
(in 100 μL of immobilization buffer containing 100 mM NaCl, 20 mM HEPES pH 7.4, 5 mM
MgCl2, 3 mM EDTA) was covalently immobilized via primary amines using N-
oxysuccinimide surface chemistry (“DNA-Bind” 96-well plates from Corning Costar;
Kennebunk, ME). After five 200 μL rinses with a wash-buffer containing 150 mM NaCl, 20
mM Tris pH 8, 0.05% Tween-20 and 0.1% BSA, immobilized membranes were incubated with
100 μL of buffer only (immobilization buffer containing an optimized concentration of
GTPγS) or buffer containing the agonist carbachol (100 μM) in the absence or presence of
indicated concentrations of the antagonist atropine. Guanine nucleotide exchange was allowed
to proceed for 20 minutes at room temperature, followed by quenching with the addition of
100 μL detection buffer (150 mM NaCl, 100 μM GDP, 0.05% Tween-20, 0.1% BSA, and 1
nM of N-terminally biotinylated KB-1755 peptide pre-adsorbed to Neutravidin-Alkaline
Phosphatase (NA-AP; Pierce). After 1 hour incubation, wells were rinsed five times with wash-
buffer and bound peptide/NA-AP complex detected with the addition of 100 μL CDP-Star
(Perkin-Elmer) and luminescence detection using a BMG Lumistar plate-reader. (B) Peptide-
based assay of β2-adrenergic receptor (β2-AR) stimulation and inhibition. Membranes of Sf9
insect cells co-infected with baculoviruses expressing β2-AR, chimeric Gαi6s (see text for
details), and Gβ1γ2 subunits were stimulated with the specific adrenergic agonist isoproterenol
(0.2 μM) in the absence or presence of indicated concentrations of the inverse agonist
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ICI-118,551. (C) Peptide-based assay of D1-dopamine receptor (D1-R) stimulation.
Membranes of Sf9 insect cells co-infected with baculoviruses expressing D1-R, chimeric
Gαi6s, and Gβ1γ2 subunits were stimulated with indicated concentrations of the specific agonist
CY 208–243. (D) Peptide-based assay of β2-AR stimulation by full and partial agonists at the
indicated concentrations, conducted as in panel (B).
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A pilot, peptide-based screening assay for activators of the M2-muscarinic acetylcholine
receptor (M2-mAChR). Intact Sf9 cells were used as the source membrane material. Sf9 cells
infected with baculoviruses encoding the M2-mAChR receptor, Gαi1, and Gβ1γ2 subunits were
washed with phosphate-buffered saline and applied to DNA-Bind 96-well plates at a density
of 500,000 cells per well. Compounds from the LOPAC library (Sigma-Aldrich) were applied
at a final concentration of 1 μM. Compound additions and washing steps were performed with
an automated liquid handling device (Tecan, Durham, NC). Results are depicted graphically,
with a ‘hit’ being defined as a response greater than 50% of the signal observed with a saturating
dose of oxotremorine (10 nM).
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Peptide-based measurements of M2-mAChR activation confirming agonist activity of TMB-8.
(A) TMB-8 is an equipotent partial agonist of the M2-mAChR as compared to carbachol. (B)
Dose-dependent atropine antagonism of carbachol- and TMB-8-agonist activity (10 μM of
either agonist). Assays were performed essentially as described in Figure 8A. (C) Nucleotide
(and concentration) dependence of the peptide-based measurement of agonist activity on the
M2-mAChR by carbachol and TMB-8.
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Table I
Specific G-protein subunit binding peptides discussed in this review
Name Peptide sequence (N-terminal to C-terminal) Binding specificity and relative affinities Reference(s)
KB-752 SRVTWYDFLMEDTKSR Gαi1/i2/i3·GDP > Gαs·GDP > Gαo·GDP [22,23,64]
KB-1753 SSRGYYHGIWVGEEGRLSR Gαi1/i2/i3/t·GDP·AlF4
− (Figure 4A,D) [21]
KB-1746 SSSYSEHCQRWGCYARLSR Gαi1/i2/i3/t/o·GDP·AlF4
− (Figure 4B,E) This study
KB-1755 SSRLCPEWICPWEWPASSR Gαt·GDP·AlF4
− > Gαi1/i2/i3·GDP·AlF4
− (Figure 4C,F) This study
R6A MSQTKRLDDQLYWWEYL Gαi1/i2/i3·GDP [35]
R6A-1 DQLYWWEYL Gα·GDP [32,39]
SIRK SIRKALNILGYPDYD Gβ1γ2 [40]
SIGK SIGKAFKILGYPDYD Gβ1γ2 [45]
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